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ABSTRACT
Autologous hematopoietic stem cell transplantation (AHSCT) in low-grade non-Hodgkin lymphoma (NHL) can
result in a prolonged remission, although most patients eventually relapse and die of their disease. We report
long-term outcomes of AHSCT for patients with relapsed low-grade NHL. Between May 1983 and 2001, 67
patients with relapsed or refractory stage III and IV low-grade NHL received an AHSCT at the University of
Minnesota at amedian of 2.3 years (range, 0.4-15.2 years) after diagnosis. At transplantation, 62 patients (92%)were
in complete remission (CR) (6%) or partial remission (PR) (86%); 5 (8%) had resistant disease; and 9 (14%) had
transformed to a higher-grade NHL. After AHSCT, 32 (49%) of 65 evaluable patients achieved CR, and 26 (40%)
achieved PR. Overall survival (OS) was 50% (95% confidence interval [CI], 38%-62%) at 4 years and 33% (95%CI,
20%-46%) at both 10 and 18 years, whereas progression-free survival (PFS) was 28% (95% CI, 17%-39%) at 4
years, 18% (95% CI, 8%-28%) at 10 years, and 14% (95% CI, 4%-25%) at 18 years. Transplant-related mortality
in the first 100 days was 3% (95% CI, 0%-7%). Relapse occurred in 62% (95% CI, 48%-75%) at 4 years and 72%
(95% CI, 56%-87%) at 10 years. Eleven patients (16%) developed myelodysplastic syndrome/acute myeloid
leukemia 1 to 8 years after AHSCT, and 3 (5%) developed solid tumors. In multiple regression analysis, the
International Prognostic Index (IPI) score at transplantation was the most significant predictor for both OS and
PFS. ThemedianOS has not been reached in patients with an IPI score of 0 or 1 at transplantation (20 of 35 survive
2 to 18 years after AHSCT), whereas it was 2.3 and 1.6 years for IPI scores of 2 and 3, respectively (P  .002). A
good response (CR/PR) to AHSCT (relative risk [RR], 0.4; 95% CI, 0.2-0.9; P  .04) and age <50 years (RR, 0.5;
95% CI, 0.2-0.8; P  .01) were also independently significant predictors of good OS and PFS. We present mature
follow-up data (median follow-up, 8 years; range, 2-18 years) of patients undergoing AHSCT for relapsed low-grade
NHL and demonstrate extended OS and PFS. Very long-term remissions were seen in nearly 20% of patients.
AHSCT remains promising, especially for patients with sensitive relapse and lower IPI scores. Recurrent lymphoma
after AHSCT remains the major problem, and prolonged survival is further tempered by a significant risk of
post-transplantation second malignancies, including myelodysplastic syndrome/acute myeloid leukemia and solid
tumors.
© 2005 American Society for Blood and Marrow Transplantation
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eNTRODUCTION
Low-grade non-Hodgkin lymphomas (NHL), of
hich follicular lymphoma is the most common his-
ology, represent tumors that are sensitive to both
hemotherapy and radiation therapy. However, these p
B&MTumors are characterized by repeated remissions and
elapses, and cure is rare. The median survival from
iagnosis in low-grade NHL ranges from 7 to 10 years
1-3], but it diminishes signiﬁcantly with relapsed dis-
ase [4]. Autologous hematopoietic stem cell trans-
lantation (AHSCT) may offer longer-term remis-
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1ions in relapsed low-grade NHL, with 4-year median
verall survival (OS) rates of 60% to 84% and pro-
ression-free survival (PFS) rates of 43% to 59% [4].
e report late outcomes and complications of
HSCT for low-grade NHL in 67 patients who un-
erwent transplantation at our institution.
ATIENTS AND METHODS
atient Characteristics and Criteria for Eligibility
Sixty-seven patients with low-grade NHL under-
ent an autologous bone marrow transplantation
BMT) or peripheral blood stem cell transplantation at
he University of Minnesota between May 1983 and
ay 2001. The patients’ histology was reviewed at trans-
lantation and classiﬁed according to the Working For-
ulation [5]. Patients were eligible for AHSCT if they
ad relapsed after standard chemotherapy or had pro-
ressive disease on conventional treatment. Patients who
ad transformed into higher-grade NHL, those with
ersistent bone marrow (BM) disease and those with
elapsed refractory disease were still considered eligible
or AHSCT. Seventeen patients had minimal BM dis-
ase (10%), whereas 20 had10% involvement (max-
mum 40%). All patients signed a written informed con-
ent before transplantation.
ata Collection
In all cases, baseline demographic data, stage of
he disease, pretransplantation chemotherapy, re-
ponse to initial chemotherapy, dates of diagnosis and
reatment, survival, and relapse were obtained from
he University of Minnesota transplant database,
hich contains prospectively collected data on all
ransplant patients at our institution. This was supple-
ented by individual medical record reviews for re-
ponse after transplantation, complications and toxic-
ty, and disease relapse or progression. Disease status
as assessed immediately before transplantation and
hen afterward at day 28 and day 100. Patients were
ubsequently re-staged every 3 months in the ﬁrst
ear, every 6 months in the second and third years,
nd yearly thereafter. Evaluation of patients consisted
f a history and physical, laboratory work including
erum lactate dehydrogenase (LDH), body computed
omographic (CT) scan, and bilateral BM biopsies.
efinitions
Disease Stage. Staging was based on the Ann Arbor
taging system [6]. Sites of involvement considered as
xtranodal included BM, liver, skin, lung, gastrointesti-
al tract, kidneys, and brain. Bulky disease or high tumor
urden was deﬁned as 3 lymph nodes sites 3 cm in
iameter, a single lymph node site 7 cm in diameter,
arked splenomegaly, or a mediastinal mass more than
ne third of the thoracic diameter. c
30The International Prognostic Index (IPI) score [7]
as calculated for all patients before transplantation.
or the purpose of calculating the IPI score, all pa-
ients were assumed to have a good performance status
t AHSCT, and hence the maximum IPI attainable for
ny patient was 4. A low IPI score was deﬁned as 0 and
, whereas a high IPI score was 2 to 4.
Response Criteria. Complete remission (CR) was
eﬁned as a complete absence of disease on physical
xamination, body CT scan, and BM. Partial remis-
ion (PR) was deﬁned as 50% reduction in involved
ymph nodes by physical examination and CT scan
nd 10% BM involvement with lymphoma. A lesser
esponse from pretransplantation salvage chemother-
py was deﬁned as resistant relapsed.
Time to engraftment was deﬁned as the time to
chieve an absolute neutrophil count 0.5  109/L
or 3 days. Progressive disease after transplantation
as deﬁned as any clinical, radiologic, or pathologic
vidence of new disease or disease progression after a
revious CR or PR.
Transplant-related mortality (TRM) was deﬁned
s death not related directly to relapse of lymphoma
nonrelapse mortality). This included mortality sec-
ndary to sepsis, veno-occlusive disease, interstitial
neumonitis, myelodysplastic syndrome (MDS), and
cute myeloid leukemia. Patients who had disease re-
urrence at the time of death were analyzed according
o the leading cause of death.
ollection, Processing, and Infusion of
ematopoietic Stem Cells
Twenty-six (39%) patients received BM, and 40
60%) received peripheral blood as their source of
tem cells. One patient received both BM and periph-
ral blood stem cells because of inadequate peripheral
lood stem cell collection. Fifteen patients (22%) who
nderwent a BMT received marrow purged in vitro
ith 3 monoclonal antibodies: BA1 (CD24), BA2
CD9), and/or BA3 (CD10) plus complement [8].
Beginning in 1995, patients who underwent pe-
ipheral blood stem cell transplantation (n 22; 33%)
eceived 2 cycles of priming before stem cell collec-
ion. Priming was started with ﬁlgrastim 250 g/m2
ubcutaneously each day on days 1 to 4 followed by
pheresis on days 5 to 7. A second collection cycle was
receded by priming chemotherapy with intravenous
IV) cyclophosphamide 4 g/m2 and cytarabine 1 g/m2
V twice daily on day 1, mitoxantrone 8 mg/m2 on day
, and dexamethasone 20 mg/m2 IV twice daily for 4
oses on days 1 and 2 in addition to daily ﬁlgrastim.
onditioning Regimen and
osttransplantation Measures
The pretransplantation conditioning regimen in-
luded cyclophosphamide 60 mg/kg IV daily for 2
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Autografts for Low-Grade NHL
Bays (7 and 6), followed by fractionated total body
rradiation (TBI) 165 cGy twice daily for 4 days (4,
3, 2, and 1), totaling 1320 cGy delivered at 5 to
0 cGy/min with a 10-MV linear accelerator (n  55;
8%). From 1983 to 1989, patients ineligible for TBI
ecause of previous irradiation received BCNU (car-
ustine) 600 mg/m2 on day 6, cyclophosphamide
0 mg/kg IV on days 5, 4, and 3, and cytarabine
00 mg/m2 IV twice daily on days 5, 4, and 3
n  2; 3%). From 1989 to 2001, patients ineligible
or TBI received cyclophosphamide 1.5 g/m2 for 4
ays (6 to 3), BCNU 300 mg/m2 day 6, and
toposide 150 mg/m2 twice daily for 3 days (days 6
o 4; n  6; 9%). Beginning in 1993, patients re-
eived ﬁlgrastim commencing at day 0 (n  40; 60%).
All patients received antifungal and antibacterial
rophylaxis. Febrile episodes were investigated and
reated promptly with broad-spectrum antibiotics.
ystemic antifungal therapy was empirically given for
nexplained persistent fevers. Transfusion support
ith irradiated blood products was performed accord-
ng to conventional indications.
tatistical Methods and Analysis
Primary end points for this study were OS and
FS. Secondary end points included CR and overall
CR  PR) response, relapse, TRM, and incidence of
DS or acute myeloid leukemia (AML).
OS and PFS were determined by using the
aplan-Meier estimation [9] with 95% conﬁdence in-
ervals (CI) derived from standard errors. Patients
ere censored at the date of last contact alive.
Cumulative incidence methods [10] were used to
stimate TRM, posttransplantation response, and
robability of relapse, progression, or secondary can-
ers. Multiple regression analysis with the Cox model
11] was used to identify predictors of survival, and
ogistic regression was used for predictors of treat-
ent response. A stepwise regression with forward
election was used; a signiﬁcance level of .10 was
equired to enter into the model and .15 to stay in the
odel.
ESULTS
atient Characteristics
The clinical characteristics of the 67 patients are
iven in Table 1. The median age at transplantation was
7 years (range, 21-66 years). The median time from
iagnosis to AHSCT was 2.3 years (range, 0.4-15.2
ears); 12 patients (18%) were beyond 5 years from
iagnosis. Fifty-two patients (78%) had stage III or IV
isease before transplantation, and 57 patients (85%) had
eceived2 regimens of chemotherapy before AHSCT.
ourteen (21%) patients underwent transplantation in
rst remission (CR or PR), 33 (49%) underwent trans- h
B&MTlantation in second remission (CR or PR), and 20
30%) received a transplant in third or subsequent re-
ission. Four patients (6%) were in CR at the time of
ransplantation, 58 (86%) were in PR, and the rest (8%)
able 1. Patient Characteristics
Variable
At Diagnosis At AHSCT
n % n %
ge, y, median (range) 42 (19-61) 47 (21-66)
ex
Male 43 64
Female 24 36
istology at diagnosis
Small cell lymphocytic 3 4
Follicular small
cleaved 44 66
Follicular mixed 14 21
Follicular large 6 9
tage
I-II 15 22
III-IV 52 78
umber of previous
chemotherapy
regimens
1 10 15
2 23 35
>2 34 50
istologic
transformation 9 14
xtranodal involvement
Bone marrow 38 57 37 55
>1 extranodal site 15 22 9 13
adiation before
AHSCT 9 14
erum LDH at
transplantation
Increased 24 36
Normal 43 64
PI score
0-1 33 49
2-3 34 51
tatus at transplantation
CR 1/PR 1 14 21
CR 2/PR 2 33 49
>CR 3/PR 3 15 22
RR 5 8
onditioning regimen
Cy/TBI 59 88
Cy/Ara-C/BCNU 2 3
Cy/VP-16/BCNU 6 9
uration of first
remission
<12 mo 41 62
>12 mo 26 38
ource of stem cells
BM 26 39
PBSC 40 59
Both 1 2
HSCT indicates autologous hematopoietic stem cell transplanta-
tion; LDH, lactate dehydrogenase; IPI, International Prognostic
Index; CR, complete remission; PR, partial remission; RR, re-
sistant relapse; Cy, cyclophosphamide; Ara-C, cytarabine;
BCNU, carmustine; TBI, total body irradiation; BM, bone mar-
row; PBSC, peripheral blood stem cells.ad resistant disease. Nine patients (14%) had trans-
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1ormed to an aggressive histology before transplantation,
ost commonly to diffuse large-cell NHL. Thirty-seven
atients (55%) had persistent BM involvement at the
ime of AHSCT. Surviving patients had been followed
p for a median of 8 years (range, 2-18 years) after
HSCT.
esponse of Lymphoma to Transplantation
Two patients were not evaluable for response be-
ause of death in the ﬁrst 30 days after AHSCT. CR
as achieved in 32 (49%) of 65 evaluable patients,
hereas 26 (40%) patients achieved a PR. Persistent
isease was documented in 7 patients (11%).
S and PFS
The probability of survival was 64% (95% CI,
3%-76%), 50% (95% CI, 38%-62%), 33% (95% CI,
0%-46%), and 33% (95% CI, 20%-46%) at 2, 4, 10,
nd 18 years after AHSCT (Figure 1a), whereas the
robability of PFS was 36% (95% CI, 24%-47%),
8% (95% CI, 17%-39%), 18% (95% CI, 8%-28%),
nd 14% (95% CI, 4%-25%) at 2, 4, 10, and 18 years
fter AHSCT (Figure 1b). Overall, 41 (61%) of the 67
atients died; most (n  24; 59% of deaths) died
ithin the ﬁrst 2 years after transplantation. Relapse
r progressive lymphoma accounted for 34 (83%) of
1 deaths. Three patients (5%) died in the early post-
ransplantation period (100 days). One died second-
igure 1. Overall survival (a) and progression-free survival (b) post
HSCT.ry to diffuse alveolar hemorrhage, 1 secondary to a
32eno-occlusive disease of the liver, and 1 because of
ardiac failure. The cumulative incidence of TRM at 4
ears (11%; 95% CI, 3%-16%) is shown in Figure 2a.
hree patients died from complications of MDS/
ML with evidence of relapsed lymphoma.
Thirteen patients (20%) are still alive and in CR at 8
o 18 years after AHSCT. One of the 9 patients who had
ransformed disease before transplantation is in CR at 14
ears after AHSCT, and 3 others are surviving with
table disease at 3 to 11 years after AHSCT.
We also analyzed separately the group of patients
ho had transformed disease and those who did not
nd found that there was no statistical difference in
S between the 2 groups. OS for the patients whose
isease did not transform was 67% (95% CI, 54%-
9%), 50% (95% CI, 37%-63%), and 30% (95% CI,
6%-44%) at 2, 4, and 10 years, respectively, whereas
S for the group who had transformed disease was
4% (95% CI, 12%-77%) at 2, 4, and 10 years, re-
pectively (P  .90).
elapse/Progressive Disease after AHSCT
Relapse or progressive disease occurred in 47
70%) patients after transplantation. The median time
o disease progression was 1.5 years (range, 0-11
ears). The cumulative incidence of relapse/disease
rogression was 55% (95% CI, 42%-69%) at 2 years,
igure 2. Cumulative incidence of transplant-related mortality (a)
nd relapse (b).
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B2% (95% CI, 48%-75%) at 4 years, and 72% (95%
I, 56%-87%) at 10 years after transplantation (Fig-
re 2b). No patient had disease progression beyond 12
ears after AHSCT.
redictors of a Good Posttransplantation
esponse (CR or PR)
In univariate analysis, a normal LDH (98% re-
ponse [n  40] versus 69% response [n  18]; P 
002) and a low IPI score at transplantation (0-1 versus
-3; P  .03) were signiﬁcant predictors of a good
esponse (CR or PR) after transplantation. In multiple
egression analysis, a low IPI score at transplantation
as a signiﬁcant independent predictor of a good
esponse (odds ratio, 10; 95% CI, 1-88; P  .01). Age,
tage at AHSCT, number of chemotherapy regimens
efore AHSCT, pathologic diagnosis, and transfor-
ation before transplantation were not signiﬁcant
redictors of response.
redictors of Good OS and PFS
In univariate analysis, age50 years (P .005), an
PI score of 0 or 1 (P  .003), and a good response
fter transplantation (CR or PR; P  .04) were all
ssociated with better PFS. Longer survival was seen
n patients 50 years old (P  .09), those with a
ormal LDH (P .0005) and a low IPI score (IPI 0 or
) at transplantation (P  .0008; Figure 3), those in
Figure 3. IPI Score at AHSCT as a predictor of survival.sFigure 4. Remission status at AHSCT as predictor of survival.
B&MTR/PR 1 or 2 versus more advanced disease (P  .08;
igure 4), and those who had a good response after
ransplantation (CR  PR versus others; P  .001).
he IPI score at AHSCT was an independently sig-
iﬁcant predictor of OS (Table 2). The median sur-
ival has not been reached in patients with a pretrans-
lantation IPI of 0 or 1 and was 2.3 years (95% CI,
.0-5.2 years) with a pretransplantation IPI of 2 and
.6 years (95% CI, 1.3-2.7 years) with a pretransplan-
ation IPI of 3 (P  .002).
In multivariate analysis, attainment of CR or PR
fter AHSCT (P  .04) and a low IPI score (0 or 1;
 .04) at AHSCT were each independent, signiﬁ-
ant predictors of good OS. A low IPI score (P .003)
nd age 50 years (P  .01) were independent pre-
ictors of improved PFS. Neither pretransplantation
esponse, nor the interval between diagnosis and
ransplant, nor the duration of ﬁrst remission, nor
urging of the BM, nor the source of the stem cells
as a predictor of survival.
redictors of Early Mortality (within 2 Years after
ransplantation)
Forty-one patients (61%) survived beyond 2 years,
lthough late deaths were seen up to 10 years after
HSCT. We conducted a landmark analysis at 2 years
o identify predictors associated with early nonrelapse
ortality and factors associated with improved sur-
ival beyond 2 years after transplantation. Nonrelapse
ortality in the ﬁrst 2 years was higher in patients
ged 50 years (RR, 2.6; 95% CI, 1.4-5.1; P  .004),
atients with bulky disease at transplantation (RR, 1.9;
5% CI, 0.9-3.8; P  .07), patients with a high IPI
able 2. Multivariate Analysis
Variable RR
95%
CI P Value
redictor of good OS
CR/PR after transplantation 0.4 0.2-0.9 .04
IPI score at Transplantation
(0 or 1 versus 2 or 3) 0.5 0.2-0.9 .04
redictor of good PFS
Recipient age at transplantation
(>50 versus <50 y) 0.5 0.2-0.8 .01
IPI score at transplantation
(0 or 1 versus 2 or 3) 0.4 0.2-0.7 .003
redictor of early TRM
Age at transplantation (>50
versus <50 y) 2.6 1.4-5.1 .004
Bulky disease 1.9 0.9-3.8 .07
<CR/PR after transplantation 3.1 1.3-6.9 .007
IPI (2 or 3 versus 0 or 1) at
transplantation 1.5 0.8-2.8 .18
R indicates complete remission; PR, partial remission; PFS, pro-
gression-free survival; IPI, International Prognostic Index;
TRM, transplant-related mortality; CI, conﬁdence interval; OS,
overall survival.core at transplantation (RR, 1.5; 95% CI, 0.8-2.8;
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1 .18), and patients not attaining a CR or PR after
ransplantation (RR, 3.1; 95% CI, 1.3-6.9; P  .007).
arly overall mortality was also worse in patients who
eceived more than 2 prior chemotherapy regimens
RR, 1.9; 95% CI, 0.9-3.7; P  .07).
redictors of OS in Patients Surviving >2 Years
fter Transplantation
Patients attaining a CR or PR after AHSCT (RR,
.5; 95% CI, 0.2-1.06; P  .07) and patients with a
ow IPI score (0 or 1) at AHSCT (RR, 0.5; 95% CI,
.2-0.9; P  .05) had a signiﬁcantly better probability
f survival beyond 2 years after AHSCT.
DS and Secondary Cancers
Eleven (16%) patients developed MDS or AML at
to 8 years after transplantation. The cumulative
ncidence of MDS/AML after AHSCT was 9% (95%
I, 1%-16%) at 2 years, 13% (95% CI, 4%-22%) at
years, and 20% (95% CI, 9%-32%) at 8 years. All
atients had been previously exposed to alkylator-
ased therapy and received TBI with pretransplanta-
ion conditioning. Ten of these patients died between
and 10 years after transplantation (0-3 years after the
iagnosis of MDS). Three patients died as a result of
omplications predominantly related to MDS/AML,
hereas the others had progressive NHL as well as
DS. Three patients (5%) developed secondary can-
ers (1 adenocarcinoma of unknown primary, 1 squa-
ous cell carcinoma of the lung, and 1 esophageal
denocarcinoma), and all died within 1 year of the date
f their cancer diagnosis.
ISCUSSION
Conventional management of low-grade NHL
as no curative options. We analyzed long-term fol-
ow-up of patients after AHSCT for relapsed low-
rade NHL and demonstrated prolonged remission in
0% well beyond 8 years from AHSCT.
Improved survival in transplanted patients with
ow-grade NHL was observed in the recently pub-
ished Chemotherapy versus Unpurged or Purged
rial, which randomized patients with relapsed but
hemotherapy-sensitive follicular lymphoma to either
onventional chemotherapy or AHSCT (46% at 4
ears versus 71% and 77%, respectively) [4].
ohatiner et al. [12] compared the outcomes from
HSCT with those of historical matched patients and
ound that the median time to recurrence was in-
reased from 1 to 4 years (P  .001) in the trans-
lanted compared with the chemotherapy cohort.
The optimal time to initiate transplantation ther-
py for patients with low-grade NHL remains uncer-
ain, although earlier seems to be better. In this study,
e observed a survival advantage in patients who un- A
34erwent transplantation in ﬁrst and second remission
ompared with later remissions. In addition, early
ortality in the 2 years was also higher in patients
ho received an AHSCT beyond the second remis-
ion. In a study from the University of Nebraska, the
umber of prior chemotherapy regimens was the only
actor signiﬁcantly associated with both OS and PFS
13]. Transplantation beyond second remission had
igniﬁcantly inferior results in the report by the
rench multicenter group [14].
We observed that the pretransplantation IPI score
as an important predictor of both OS and PFS after
HSCT. This is in keeping with the predictive value
f the IPI score on outcomes after AHSCT in diffuse
arge B-cell lymphoma [15]. In low-grade NHL, the
PI has been also found to be useful for selecting
igh-risk patients and for predicting survival after
rogression [16].
Part of the natural history of low-grade NHL is
he potential transformation into a more aggressive
istology. This has been associated with a more ag-
ressive course and poorer prognosis [17]. Out of 9
atients whose disease transformed into a higher-
rade NHL in our study, 1 remains in CR, and 3 have
table disease after AHSCT. This suggests that some
atients with transformed low-grade NHL may still
chieve prolonged survival with AHSCT. Prolonged
emission was reported by the Dana-Farber Cancer
nstitute, where patients with transformed but chemo-
ensitive low-grade NHL received a purged BM graft,
nd the PFS at 5 years was 46% [18].
A major late complication after AHSCT is the
evelopment of second cancers, particularly MDS/
ML. In our cohort, 16% of patients developed
DS/AML. A similar incidence of MDS and AML
ver a 15-year period has been reported after the
ombination of low-dose TBI and cytotoxic chemo-
herapy for low-grade NHL [19]. This incidence may
xceed that expected with conventional chemotherapy
lone, although longer survival and closer follow-up of
ransplant recipients may increase ascertainment and
eporting of secondary MDS/AML. This observation
s supported by a study from the University of
ebraska, in which age 40 years and the use of TBI
n the preparative regimen were identiﬁed as signiﬁ-
ant risk factors for developing post-BMT MDS in
atients with NHL [20]. Transplantation in earlier
emissions may reduce this risk because patients are
xposed to fewer chemotherapy regimens.
Low-grade NHL remains a very challenging dis-
ase to manage, and the role of hematopoietic stem
ell transplantation in this disease is still unclear. We
eport that long-term and durable remission may be
een in selected patients with low-grade NHL, espe-
ially those with a low IPI score and chemosensitive
elapse. It is, however, difﬁcult to ascertain whether
HSCT changes the course of this illness [21]. Pa-
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Bients with refractory disease or a high IPI score do
oorly with AHSCT and should be considered for
ovel therapies, such as monoclonal antibodies, radio-
mmunotherapy, or nonmyeloablative allogeneic stem
ell transplantation.
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